TARGETING THE PIK3 PATHWAY IN NON-SMALL CELL LUNG CANCER

TARGETING THE PIK3 PATHWAY IN NON-SMALL CELL LUNG CANCER

Ph.D

Saved in:

Bibliographic Details
Main Author:	DANIEL TAN SHAO WENG
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Theses and Dissertations
Language:	English
Published:	2017
Subjects:	PI3K pathway, EGFR mutant NSCLC, TKI resistance
Online Access:	http://scholarbank.nus.edu.sg/handle/10635/135882
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Similar Items

Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
by: Chin, T.-M., et al.
Published: (2021)

Blocking aerobic glycolysis by targeting pyruvate dehydrogenase kinase in combination with egfr tki and ionizing radiation increases therapeutic effect in non-small cell lung cancer cells
by: Dyrstad, Sissel E., et al.
Published: (2022)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
by: Sudo, M., et al.
Published: (2014)

CAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer
by: Ali, A., et al.
Published: (2022)

Mechanisms of resistance to pi3k inhibitors in cancer: Adaptive responses, drug tolerance and cellular plasticity
by: Wright, Sarah Christine Elisabeth, et al.
Published: (2022)

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach
by: Salto-Tellez, M., et al.
Published: (2014)

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR plus non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance
by: Ma, Jun, et al.
Published: (2024)

REGULATION OF AMPK ACTIVATION AND ITS ROLE IN CELL DEATH INDUCED BY GLUCOSE STARVATION IN LKB1-MUTANT HUMAN LUNG CANCER CELLS
by: REN YI
Published: (2019)

The IκB kinase inhibitor ACHP targets the STAT3 signaling pathway in human non-small cell lung carcinoma cells
by: Lee, J.H., et al.
Published: (2021)

Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy
by: Tan, J., et al.
Published: (2014)

EXPLORING TARGETED AND NON-TARGETED APPROACHES IN THE DEVELOPMENT OF ANTI-FIBROTIC THERAPY FOR LIVER FIBROSIS
by: SOH KAR LING CARRIE
Published: (2017)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
by: Park, Keunchil, et al.
Published: (2022)

CHARACTERIZING CISPLATIN-RESISTANT NSCLC CELLS AND IDENTIFYING TRAIL AS A POTENTIAL SECOND-LINE THERAPY IN REFRACTORY CANCER CELLS
by: SEAH BEE KEE SERENA
Published: (2013)

Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation
by: Chong, M.-L., et al.
Published: (2014)

Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer
by: Tan, E.-H., et al.
Published: (2014)

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
by: Glaviano, A, et al.
Published: (2023)

Aspirin potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer by targeting GRP78 activity
by: Zhang, X., et al.
Published: (2021)

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
by: Schuler, M, et al.
Published: (2024)

Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy
by: Limviphuvadh, Vachiranee, et al.
Published: (2018)

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
by: Chang, Gee-Chen, et al.
Published: (2022)

SRSF1-MEDIATED TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKAEMIA
by: SINNAKANNU JOANNA RAJESWARY
Published: (2018)

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
by: Nokihara, H, et al.
Published: (2022)

Analysis of P13K-independent survival pathways in the prostate cancer cell line LN CaP
by: CHAO SU PING, OLIVIA
Published: (2010)

PTEN, a barrier for proliferation and metastasis of gastric cancer cells: From molecular pathways to targeting and regulation
by: Ashrafizadeh, M., et al.
Published: (2021)

Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells
by: Bhattacharya, B., et al.
Published: (2014)

Epigenetic Small-Molecule Modulators Targeting Metabolic Pathways in Cancer
by: Das, D, et al.
Published: (2022)

IDENTIFYING THE ONCOGENIC ROLE OF USP10 IN BREAST CANCER
by: NISHI KUMARI
Published: (2019)

ACTIVATION OF PI3K/AKT PATHWAY BY DP103-P110α INTERACTION PROMOTES TUMORIGENIC CAPACITY OF GASTRIC CANCER CELLS
by: SHIKHA SATENDRA SINGH
Published: (2017)

Long-term prognostic significance of interleukin-17-producing T cells in patients with non-small cell lung cancer
by: Song, L., et al.
Published: (2021)

ZDOG: Zooming in on dominating genes with mutations in cancer pathways
by: Alberts, R., et al.
Published: (2021)

THE ONCOGENIC ROLE OF TREFOIL FACTOR 3 (TFF3) IN NON-SMALL CELL LUNG CANCER (NSCLC)
by: ZHANG MENGYI
Published: (2019)

Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china
by: You, R., et al.
Published: (2021)

Activation of the PI3K-Akt-mTOR signaling pathway promotes necrotic cell death via suppression of autophagy
by: Wu, Y.-T., et al.
Published: (2011)

Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer
by: Huang, Yiqing, et al.
Published: (2022)

Potential of tyrosine kinase receptor TIE-1 as novel therapeutic target in high-PI3K-expressing ovarian cancer
by: Zhang, X., et al.
Published: (2021)

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy
by: Soo, R.A., et al.
Published: (2014)

Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure
by: Saw, Stephanie PL, et al.
Published: (2024)

Database and software development for therapeutic proteins, pathways and herbs
by: ZHOU HAO
Published: (2019)

MiR-582-5p is a tumor suppressor microRNA targeting the Hippo-YAP/TAZ signaling pathway in non-small cell lung cancer
by: Zhu, Bowen, et al.
Published: (2022)

Brassinin represses invasive potential of lung carcinoma cells through deactivation of PI3K/Akt/mTOR signaling cascade
by: Yang, M.H., et al.
Published: (2021)